Oral montelukast and cetirizine for thyroid eye disease

Ophthalmic Plastic and Reconstructive Surgery

Volumn 24, Issue 4, 2008, Pages 257-261

  Lauer, Simeon A ^a,b,d   Silkiss, Rona Z ^c   McCormick, Steven A ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW YORK EYE AND EAR INFIRMARY   (United States)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETIRIZINE; CORTICOSTEROID; MONTELUKAST; ACETIC ACID DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR BLOCKING AGENT; QUINOLINE DERIVATIVE;

ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIPLOPIA; DRUG EFFICACY; ENDOCRINE OPHTHALMOPATHY; EVENING DOSAGE; EYE SWELLING; EYELID RETRACTION; HUMAN; MORNING DOSAGE; OCULAR PRURITUS; PRIORITY JOURNAL; ADIPOSE TISSUE; CLINICAL TRIAL; DRUG COMBINATION; EXTRAOCULAR MUSCLE; FEMALE; MALE; MAST CELL; MIDDLE AGED; ORAL DRUG ADMINISTRATION; ORBIT; PATHOLOGY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ACETATES; ADIPOSE TISSUE; ADMINISTRATION, ORAL; CETIRIZINE; DRUG THERAPY, COMBINATION; FEMALE; GRAVES OPHTHALMOPATHY; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; MAST CELLS; MIDDLE AGED; OCULOMOTOR MUSCLES; ORBIT; QUINOLINES; TREATMENT OUTCOME;

EID: 48849089333     PISSN: 07409303     EISSN: None     Source Type: Journal    
DOI: 10.1097/IOP.0b013e318177ebac     Document Type: Article

References (30)

1. Boschi A, Daumerie C, Spiritus M, et al. Quantification of cells expressing the thyrotropin receptor in extraocular muscles in thyroid associated orbitopathy. Br J Ophthalmol 2005;89:724-729 (Pubitemid 40780581)
2. Mizokami T, Salvi M, Wall JR. Eye muscle antibodies in Graves' ophthalmopathy: pathogenic or secondary epiphenomenon? J Endocrinol Invest 2004;27:221-229 (Pubitemid 38607474)
3. Segundo C, Rodriguez C, Aguilar M, et al. Differences in thyroid-infiltrating B lymphocytes in patients with Graves' disease: relationship to autoantibody detection. Thyroid 2004;14:337-344 (Pubitemid 38756651)
4. Hufnagel TJ, Hickey WF, Cobbs WH, et al. Immunohistochemical and ultrastructural studies on the exenterated orbital tissues of a patient with Graves' disease. Ophthalmology 1984;91:1411-1419
5. Smith TJ. Novel aspects of orbital fibroblast pathology. J Endocrinol Invest 2004;27:246-253
6. Bahn RS, Heufelder AE. Retrobulbar fibroblasts: important effector cells in Graves' ophthalmopathy. Thyroid 1992;2:89-94.
7. Gurish MF, Boyce JA. Mast cells: ontogeny, homing, and recruitment of a unique innate effector cell. J All Clin Immunol 2006; 117:1285-1291
8. Nigrovic PA, Lee DM. Mast cells in inflammatory arthritis. Arthritis Res Ther 2005;7:1-11.
9. Cockerham KP, Hidayat AA, Brown HG, et al. Clinicopathologic evaluation of the Müller muscle in thyroid-associated orbitopathy. Ophthal Plast Reconstr Surg 2002;18:11-17.
10. Ludgate ME. Animal models of thyroid-associated ophthalmopathy. Thyroid 2002;205-208
11. Ludgate M, Baker G. Inducing Graves' ophthalmopathy. J Endocrinol Invest 2004;27:211-215
12. Yamada M, Li AW, West KA, et al. Experimental model for ophthalmopathy in BALB/c and outbred (CD-1) mice genetically immunized with G2s and the thyrotropic receptor. Autoimmunity 2002;35:403-413 (Pubitemid 35252232)
13. Spinozzi F, Russano AM, Piattoni S, et al. Biological effects of montelukast, a cysteinyl-leukotriene receptor-antagonist, on T lymphocytes. Clin Exp Allergy 2004;34:1876-1882 (Pubitemid 40023638)
14. Busse W, Kraft M. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest 2005;127:1312-1326 (Pubitemid 46224296)
15. Dawicki W, Marshall JS. New and emerging roles for mast cells in host defence. Curr Opin Immunol 2007;19:31-38 (Pubitemid 46073696)
16. Fehrenbach K, Port F, Grochowy G, et al. Stimulation of mast cells via FcvarepsilonR1 and TLR2: the type of ligand determines the outcome. Mol Immunol 2007;44:2097-2104 (Pubitemid 44827242)
17. Frankenstein Z, Alon U, Cohen IR. The immune-body cytokine network defines a social architecture of cell interactions. Biol Direct 2006;1:32. (Pubitemid 46711927)
18. Ogawa Y, Calhoun WJ. The role of leukotrienes in airway inflammation. J Allergy Clin Immunol 2006;118:789-798
19. Fireman E, Schwartz Y, Mann A, Greif J. Effect of montelukast, a cysteinyl receptor antagonist, on myofibroblasts in interstitial lung disease. J Clin Immunol 2004;24:418-425 (Pubitemid 39005574)
20. Kuna P, Gorski P. Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal allergic inflammation. Allergy 2004; 59:276-279 (Pubitemid 38339844)
21. Lee DKC, Jackson CM, Soutar PC, et al. Effects of single or combined histamine H1-receptor and leukotriene CysLT1-receptor antagonism on nasal adenosine monophosphate challenge in persistent allergic rhinitis. Br J Clin Pharmacol 2004;57:714-719
22. Storms W, Kaliner MA. Cromolyn sodium: fitting an old friend into current asthma treatment. J Asthma 2005;42:79-89. (Pubitemid 40575746)
23. Barbie DA, Deangelo DJ. Systemic mastocytosis: current classification and novel therapeutic options. Clin Adv Hematol Oncol 2006;4:768-775
24. Guevara JP, Ducharme FM, Keren R, et al. Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma. Cochrane Database Syst Rev 2006;2:CD003558.
25. Ebihara N, Nishikawa M, Murakami A. Disodium cromoglycate inhibits capsaicin-induced eosinophil infiltration of conjunctiva independent of mast cells. Jpn J Ophthalmol 2006;50:205-210 (Pubitemid 43881993)
26. Grainger J, Drake-Lee A. Montelukast in allergic rhinitis: a systematic review and meta-analysis. Clin Otolaryngol 2006;31:360-367 (Pubitemid 44511155)
27. Weinstein SF, Philip G, Hampel FC Jr, et al. Onset of efficacy of montelukast in seasonal allergic rhinitis. Allergy Asthma Proc 2005;26:41-46 (Pubitemid 40521988)
28. Duchemin J, Lion F, Arnaud B, et al. Acquired thrombopathia related to montelukast therapy. Thromb Haemost 2004;91:1247-1248 (Pubitemid 38821284)
29. Minciullo PL, Saija A, Bonanno D, et al. Montelukast-induced generalized urticaria. Ann Pharmacother 2004;38:999-1001.
30. Conen D, Leuppi J, Bubendorf L, et al. Montelukast and Churg- Strauss syndrome. Swiss Med Wkly 2004;134:377-380